查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947928

中枢神经系统治疗市场分析及预测（至2035年）：依类型、产品、技术、应用、最终用户、製程、设备、阶段及给药途径划分

Central Nervous System Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Device, Stage, Mode
出版日期: | 出版商: Global Insight Services | 英文 380 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，中枢神经系统治疗市场规模将从2024年的1,363亿美元成长至2,885亿美元，复合年增长率约为12.1%。该市场涵盖针对阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病的治疗方案。生物技术的进步、中枢神经系统疾病盛行率的上升以及人口老化加剧是推动该市场成长的主要因素。药物递送系统和个人化医疗的创新至关重要，其重点在于提高疗效和改善患者预后。监管支持和研发投入的增加进一步推动了市场成长，为相关人员创造了丰厚的成长机会。

中枢神经系统治疗市场正经历显着成长，这主要得益于神经系统疾病盛行率的上升和创新治疗方法的研发。神经退化性疾病领域，尤其是阿兹海默症和帕金森氏症，由于新型药物的研发和诊断技术的进步，处于领先地位。精神疾病治疗，特别是忧郁症和焦虑症的治疗，也紧随其后，反映出人们对心理健康的日益关注和认可。生物製药和小分子疗法是关键的细分市场，其中生物製药因其定向和副作用较小而备受关注。小分子疗法领域保持着强劲的成长势头，提供经济高效的解决方案和广泛的适用性。基因疗法和干细胞疗法正在迅速发展，并有望对慢性神经系统疾病产生变革性影响。对个人化医疗日益增长的需求凸显了为每位患者制定优化治疗方案的必要性。预计不断增加的研究经费以及製药公司与研究机构之间的策略联盟将进一步推动创新和市场成长。

市场区隔
按类型 神经退化性疾病、神经血管疾病、精神疾病、感染疾病、中枢神经系统创伤、自体免疫疾病、神经肿瘤学
产品 小分子化合物、生物製药、基因疗法、细胞疗法、神经刺激设备、神经保护剂
科技 CRISPR、 RNA干扰、干细胞疗法、奈米技术、生物标记、人工智慧
目的 药物研发、诊断、外科手术、復健、远端医疗、个人化医疗
最终用户 医院、诊所、研究机构、生物製药公司、学术机构
流程 临床试验、临床前研究、药物发现、监管核准和商业化
装置 植入式设备、穿戴式装置、诊断设备和治疗设备
步 早期研究、临床前研究、临床研究及商业化​​上市
给药途径 口服、注射、外用、吸入

中枢神经系统治疗市场正经历着由治疗创新和策略定价模式驱动的市场份额动态变化。随着大型製药和生技公司推出突破性治疗方法，新产品的上市正在重塑市场结构。这些进展不仅改善了患者的治疗效果，也推动了竞争激烈的定价策略。市场对先进疗法的需求激增，促使各公司加速研发投入以维持竞争优势。竞争基准研究揭示了主要产业参与者之间的激烈竞争，策略联盟和併购正在重塑竞争格局。监管影响至关重要，严格的指导方针规范市场准入和产品核可流程。北美和欧洲的法规结构仍然是影响市场动态和竞争策略的关键因素。这项全面的分析强调了了解监管影响和竞争定位对于有效驾驭中枢神经系统治疗市场的重要性。

主要趋势和驱动因素：

受全球人口老化和神经系统疾病盛行率上升的推动，中枢神经系统（CNS）治疗市场正经历显着增长。生物製药和基因疗法的进步是关键趋势，为传统上难以治疗的CNS疾病提供了极具前景的治疗选择。人工智慧在药物研发的应用正在加速新型疗法的开发，并提升精准医疗水准。此外，以病人为中心的医疗模式日益受到重视，推动了数位疗法的兴起，这些疗法是对传统治疗方法的补充。医疗保健技术和基础设施投资的不断增加也为这一转变提供了支持。监管机构也在简化创新CNS疗法的核准流程，以加速其市场准入。新兴市场蕴藏着许多机会，这些市场的医疗保健覆盖范围不断扩大，人们对CNS疾病的认知也不断提高。专注于个人化医疗和标靶治疗的公司有望占据可观的市场份额。製药公司和科技公司之间的合作正在透过数位平台推动进一步创新，这些平台能够实现对CNS疾病的即时监测和管理。这种充满活力的环境有望实现持续成长，尤其是在开发出满足未被满足的治疗方法需求的新疗法之后。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 神经退化性疾病
    • 神经血管疾病
    • 精神疾病
    • 感染疾病
    • 创伤性中枢神经系统损伤
    • 自体免疫疾病
    • 神经肿瘤学
  • 市场规模及预测：依产品划分
    • 低分子化合物
    • 生物製药
    • 基因治疗
    • 细胞疗法
    • 神经刺激设备
    • 神经保护剂
  • 市场规模及预测：依技术划分
    • CRISPR
    • RNA干扰
    • 干细胞疗法
    • 奈米科技
    • 生物标誌物
    • 人工智慧
  • 市场规模及预测：依应用领域划分
    • 药物研发
    • 诊断
    • 手术介入
    • 復原
    • 远端医疗
    • 个人化医疗
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 生物製药公司
    • 学术机构
  • 市场规模及预测：依製程划分
    • 临床试验
    • 临床前研究
    • 药物发现
    • 监管部门核准
    • 商业化
  • 市场规模及预测：依设备划分
    • 植入式装置
    • 穿戴式装置
    • 诊断设备
    • 治疗设备
  • 市场规模及预测：依阶段划分
    • 初步研究
    • 临床前
    • 临床
    • 上市
  • 市场规模及预测：依管理途径
    • 口服
    • 注射
    • 外用
    • 吸入

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Biogen
  • Jazz Pharmaceuticals
  • UCB
  • Alkermes
  • Ipsen
  • Lundbeck
  • Acadia Pharmaceuticals
  • H. Lundbeck
  • Supernus Pharmaceuticals
  • Neurocrine Biosciences
  • Sage Therapeutics
  • Amneal Pharmaceuticals
  • Otsuka Pharmaceutical
  • Sumitomo Pharma
  • Zogenix
  • Acorda Therapeutics
  • Intra-Cellular Therapies
  • GW Pharmaceuticals
  • Eisai
  • Cortexyme

第九章：关于我们

简介目录
Product Code: GIS32222

Central Nervous System Therapeutics Market is anticipated to expand from $136.3 billion in 2024 to $288.5 billion by 2034, growing at a CAGR of approximately 12.1%. The Central Nervous System Therapeutics Market encompasses treatments targeting neurological disorders, including Alzheimer's, Parkinson's, and multiple sclerosis. This market is driven by advancements in biotechnology, increasing prevalence of CNS disorders, and a growing geriatric population. Innovations in drug delivery systems and personalized medicine are pivotal, with a focus on improving efficacy and patient outcomes. Regulatory support and rising investment in R&D further propel market growth, presenting lucrative opportunities for stakeholders.

The Central Nervous System Therapeutics Market is experiencing significant advancements, fueled by an increasing prevalence of neurological disorders and innovative treatment modalities. The neurodegenerative diseases segment, particularly Alzheimer's and Parkinson's therapies, is at the forefront, driven by novel drug developments and enhanced diagnostic techniques. Psychiatric disorder treatments, especially for depression and anxiety, follow closely, reflecting an upsurge in mental health awareness and acceptance. Biologics and small molecule therapeutics are leading sub-segments, with biologics gaining prominence due to their targeted action and reduced side effects. The small molecule sector remains robust, offering cost-effective solutions and broad applicability. Gene therapy and stem cell treatments are emerging rapidly, promising transformative impacts on chronic neurological conditions. The demand for personalized medicine is rising, emphasizing the need for tailored therapeutic approaches. Increased research funding and strategic partnerships between pharmaceutical companies and research institutions are expected to drive further innovation and market growth.

Market Segmentation
TypeNeurodegenerative Diseases, Neurovascular Disorders, Psychiatric Disorders, Infectious Diseases, Traumatic CNS Injuries, Autoimmune Disorders, Neuro-oncology
ProductSmall Molecules, Biologics, Gene Therapy, Cell Therapy, Neurostimulation Devices, Neuroprotective Agents
TechnologyCRISPR, RNA Interference, Stem Cell Therapy, Nanotechnology, Biomarkers, Artificial Intelligence
ApplicationDrug Development, Diagnostics, Surgical Intervention, Rehabilitation, Telemedicine, Personalized Medicine
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies, Academic Institutions
ProcessClinical Trials, Preclinical Research, Drug Discovery, Regulatory Approval, Commercialization
DeviceImplantable Devices, Wearable Devices, Diagnostic Equipment, Therapeutic Devices
StageEarly-stage Research, Preclinical Stage, Clinical Stage, Post-Market Surveillance
ModeOral, Injectable, Topical, Inhalation

The Central Nervous System Therapeutics Market is experiencing a dynamic shift in market share, driven by innovation in treatment methodologies and strategic pricing models. New product launches are reshaping the landscape, with pharmaceutical giants and biotech firms introducing groundbreaking therapies. These developments are not only enhancing patient outcomes but also fostering competitive pricing strategies. The market is witnessing a surge in demand for advanced therapeutics, encouraging companies to invest in research and development to maintain a competitive edge. Competition benchmarking reveals a robust rivalry among key industry players, with strategic alliances and mergers shaping the competitive landscape. Regulatory influences are pivotal, with stringent guidelines dictating market entry and product approval processes. The regulatory framework in North America and Europe remains a critical factor, influencing market dynamics and competitive strategies. This comprehensive analysis underscores the importance of understanding regulatory impacts and competitive positioning to navigate the Central Nervous System Therapeutics Market effectively.

Geographical Overview:

The Central Nervous System (CNS) Therapeutics Market is witnessing notable regional growth, each with unique dynamics. North America remains preeminent, driven by substantial investments in research and development and a robust healthcare infrastructure. The presence of leading pharmaceutical companies further bolsters its market position. Europe trails closely, benefitting from strong governmental support for neurological research and increasing prevalence of CNS disorders. The Asia Pacific region is experiencing rapid expansion, fueled by rising healthcare expenditures and an aging population. Emerging economies such as China and India are at the forefront, investing heavily in healthcare advancements. Latin America and the Middle East & Africa are burgeoning markets. Brazil and Mexico are showing increased demand for CNS therapeutics, while the Middle East & Africa are recognizing the potential of CNS treatments in addressing prevalent neurological disorders, thus driving market growth and innovation.

Global tariffs and geopolitical tensions are intricately influencing the Central Nervous System Therapeutics Market. In Japan and South Korea, reliance on imported raw materials for drug manufacturing is prompting a strategic pivot towards enhancing local production capabilities and securing diversified supply sources. China is accelerating its pharmaceutical innovation, driven by export restrictions and a strategic focus on self-reliance. Taiwan, with its robust biotech sector, continues to play a pivotal role but remains sensitive to regional tensions. The global market for CNS therapeutics is experiencing robust growth, propelled by rising prevalence of neurological disorders. By 2035, the market is expected to flourish, contingent upon geopolitical stability and resilient supply chains. Middle East conflicts pose potential risks to global energy prices, indirectly affecting manufacturing and distribution costs.

Key Trends and Drivers:

The Central Nervous System (CNS) Therapeutics Market is experiencing substantial growth, driven by an aging global population and the rising prevalence of neurological disorders. Key trends include advancements in biologics and gene therapy, offering promising treatment options for previously untreatable CNS conditions. The integration of artificial intelligence in drug discovery is accelerating the development of novel therapeutics, enhancing precision medicine approaches. Moreover, there is a growing emphasis on patient-centric care, with digital therapeutics gaining traction to complement traditional treatments. This shift is supported by increasing investments in healthcare technology and infrastructure. Regulatory bodies are also streamlining approval processes for innovative CNS drugs, facilitating faster market entry. Opportunities abound in emerging markets where healthcare access is expanding, and awareness of CNS disorders is increasing. Companies focusing on personalized medicine and targeted therapies are well-positioned to capture significant market share. Collaborations between pharmaceutical companies and tech firms are further driving innovation, with digital platforms offering real-time monitoring and management of CNS conditions. This dynamic landscape is poised for continuous growth, especially as new therapeutic modalities are developed to address unmet medical needs.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Neurodegenerative Diseases
    • 4.1.2 Neurovascular Disorders
    • 4.1.3 Psychiatric Disorders
    • 4.1.4 Infectious Diseases
    • 4.1.5 Traumatic CNS Injuries
    • 4.1.6 Autoimmune Disorders
    • 4.1.7 Neuro-oncology
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Small Molecules
    • 4.2.2 Biologics
    • 4.2.3 Gene Therapy
    • 4.2.4 Cell Therapy
    • 4.2.5 Neurostimulation Devices
    • 4.2.6 Neuroprotective Agents
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 CRISPR
    • 4.3.2 RNA Interference
    • 4.3.3 Stem Cell Therapy
    • 4.3.4 Nanotechnology
    • 4.3.5 Biomarkers
    • 4.3.6 Artificial Intelligence
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Drug Development
    • 4.4.2 Diagnostics
    • 4.4.3 Surgical Intervention
    • 4.4.4 Rehabilitation
    • 4.4.5 Telemedicine
    • 4.4.6 Personalized Medicine
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Academic Institutions
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Clinical Trials
    • 4.6.2 Preclinical Research
    • 4.6.3 Drug Discovery
    • 4.6.4 Regulatory Approval
    • 4.6.5 Commercialization
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Implantable Devices
    • 4.7.2 Wearable Devices
    • 4.7.3 Diagnostic Equipment
    • 4.7.4 Therapeutic Devices
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Early-stage Research
    • 4.8.2 Preclinical Stage
    • 4.8.3 Clinical Stage
    • 4.8.4 Post-Market Surveillance
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Oral
    • 4.9.2 Injectable
    • 4.9.3 Topical
    • 4.9.4 Inhalation

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Device
      • 5.2.1.8 Stage
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Device
      • 5.2.2.8 Stage
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Device
      • 5.2.3.8 Stage
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Device
      • 5.3.1.8 Stage
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Device
      • 5.3.2.8 Stage
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Device
      • 5.3.3.8 Stage
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Device
      • 5.4.1.8 Stage
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Device
      • 5.4.2.8 Stage
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Device
      • 5.4.3.8 Stage
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Device
      • 5.4.4.8 Stage
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Device
      • 5.4.5.8 Stage
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Device
      • 5.4.6.8 Stage
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Device
      • 5.4.7.8 Stage
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Device
      • 5.5.1.8 Stage
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Device
      • 5.5.2.8 Stage
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Device
      • 5.5.3.8 Stage
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Device
      • 5.5.4.8 Stage
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Device
      • 5.5.5.8 Stage
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Device
      • 5.5.6.8 Stage
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Device
      • 5.6.1.8 Stage
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Device
      • 5.6.2.8 Stage
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Device
      • 5.6.3.8 Stage
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Device
      • 5.6.4.8 Stage
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Device
      • 5.6.5.8 Stage
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Biogen
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Jazz Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 UCB
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Alkermes
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Ipsen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Lundbeck
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Acadia Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 H. Lundbeck
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Supernus Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Neurocrine Biosciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sage Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Amneal Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Otsuka Pharmaceutical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sumitomo Pharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Zogenix
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Acorda Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Intra- Cellular Therapies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 GW Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Eisai
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cortexyme
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us